Cullinan Therapeutics (CGEM) Accumulated Expenses (2020 - 2026)

Cullinan Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $31.9 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 41.23% year-over-year to $31.9 million in Q1 2026; TTM through Mar 2026 was $31.9 million, a 41.23% increase from a year earlier, with the FY2025 full-year figure at $36.1 million, up 30.57% from the prior year.
• Accumulated Expenses retreated to $31.9 million in Q1 2026 per CGEM's latest filing, from $36.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $36.1 million in Q4 2025 and bottomed at $2.4 million in Q2 2022.
• The 5-year median for Accumulated Expenses is $20.7 million (2024), against an average of $18.1 million.
• Across the five-year window, Accumulated Expenses slumped 58.83% in 2022 and soared 766.51% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $14.1 million in 2022, then surged by 71.23% to $24.2 million in 2023, then increased by 14.29% to $27.7 million in 2024, then jumped by 30.57% to $36.1 million in 2025, then retreated by 11.63% to $31.9 million in 2026.
• Per Business Quant, the three latest CGEM Accumulated Expenses figures stand at $31.9 million (Q1 2026), $36.1 million (Q4 2025), and $29.8 million (Q3 2025).